Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05021536 · ClinicalTrials.gov registry record · Phase 3
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
A Phase 3 study of Amyotrophic Lateral Sclerosis, sponsored by Amylyx Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 664
- Enrollment target
- 20
- Study locations
NCT05021536 is a Phase 3 study of Amyotrophic Lateral Sclerosis that is active but no longer recruiting, run by Amylyx Pharmaceuticals. The registered enrollment target is 664 participants, below the 891-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05021536, a Phase 3 study of Amyotrophic Lateral Sclerosis, is active but no longer recruiting, sponsored by Amylyx Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 664 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AMX0035
Study Locations (20)
California
- University of Southern California - Los Angeles
- University of California Irvine - Orange
- California Pacific Medical Center Research Institute - San Francisco
Florida
- University of Florida - Gainesville
- University of South Florida - Tampa
Georgia
- Emory University - Atlanta
- Augusta University Neuroscience Center - Augusta
Massachusetts
- Healey & AMG Center for ALS Research at Massachusetts General Hospital - Boston
- University of Massachusetts - Worcester
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- Wake Forest University Health Sciences - Winston-Salem
Arizona
- Barrow Neurological Institute - Phoenix
Colorado
- University of Colorado - Aurora
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 664 participants |
| Start Date | 2021-10-28 |
| Est. Completion | 2026-01-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05021536
The ClinicalTrials.gov registry entry for NCT05021536 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 664 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 891-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (25% lower). The listed sponsor is Amylyx Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05021536 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05021536 about?
NCT05021536 is a clinical study titled "Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment". The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS
What is the current status of trial NCT05021536?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 664 participants. The study started on 2021-10-28. Estimated completion is 2026-01-01.
What conditions does trial NCT05021536 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT05021536?
The interventions under investigation include: Placebo (OTHER), AMX0035 (DRUG).
Who is sponsoring clinical trial NCT05021536?
This trial is sponsored by Amylyx Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05021536 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
RECRUITING · Phase 3
-
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
RECRUITING · Phase 3
-
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
ACTIVE NOT RECRUITING · Phase 3
-
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
COMPLETED · Phase 3
-
An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)
COMPLETED · Phase 3
-
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.